natural killer cells
Showing 1 - 25 of >10,000
Healthy Subjects Trial in El Segundo (N-803)
Not yet recruiting
- Healthy Subjects
-
El Segundo, CaliforniaChan Soon-Shiong Institute for Medicine
Sep 14, 2023
Pediatric Brain Tumor, Recurrent Pediatric Brain Tumor, Pediatric Supratentorial Tumor Trial in San Francisco (Universal Donor
Not yet recruiting
- Pediatric Brain Tumor
- +2 more
- Universal Donor (UD) Transforming growth factor beta imprinting (TGFβi) Natural Killer (NK) Cells
- Implantation
-
San Francisco, CaliforniaUniversity of California, San Francisco
May 24, 2023
Advanced Melanoma, Metastatic Melanoma Trial in Saint Louis (Memory-like natural killer cells, Relatilmab, Nivolumab)
Not yet recruiting
- Advanced Melanoma
- Metastatic Melanoma
- Memory-like natural killer cells
- +2 more
-
Saint Louis, MissouriWashington University School of Medicine
Nov 16, 2022
Acute Myeloid Leukemia Trial in Cincinnati (CIML-NK Cells)
Recruiting
- Acute Myeloid Leukemia
- CIML-NK Cells
-
Cincinnati, OhioCincinnati Children's Hospital Medical Center
Jan 4, 2023
Pathologically Confirmed Cancer Refractory to Conventional Therapy, Refractory Cancer, Metastatic Cancer Trial in Santa Monica
Not yet recruiting
- Pathologically Confirmed Cancer Refractory to Conventional Therapy
- +7 more
- SNK02
-
Santa Monica, CaliforniaSarcoma Oncology Center
Aug 10, 2023
Acute Myeloid Leukemia Trial in Columbus (Universal Donor Natural Killer Cells)
Recruiting
- Acute Myeloid Leukemia
- Universal Donor Natural Killer Cells
-
Columbus, OhioNationwide Children's Hospital
Aug 11, 2022
Acute Myeloid Leukemia, Leukemia, Leukemia, Myeloid Trial in Boston (Cytokine Induced Memory-like Natural Killer Cells,
Not yet recruiting
- Acute Myeloid Leukemia
- +5 more
- Cytokine Induced Memory-like Natural Killer Cells
- Interleukin-2
-
Boston, Massachusetts
- +1 more
Nov 14, 2023
Asthma Acute Trial in Marseille (blood sample)
Not yet recruiting
- Asthma Acute
- blood sample
-
Marseille, FranceHôpital NORD - AP-HM, Clinique des bronches, de l'allergie et du
Aug 22, 2023
Leukemia, Acute Myeloid, Leukemia, Acute Lymphoblastic Trial in Minsk (Expanded Haploidentical Natural Killer cells, IL-2)
Completed
- Leukemia, Acute Myeloid
- Leukemia, Acute Lymphoblastic
- Expanded Haploidentical Natural Killer cells
- IL-2
-
Minsk, Minsk Region, BelarusBelarussian Research Center for Pediatric Oncology, Hematology a
Feb 28, 2022
Chronic Myeloid Leukemia (CML), Pancreatic Ca, Colon/Rectal Ca Trial run by the National Heart, Lung, and Blood Institute
Completed
- Chronic Myeloid Leukemia (CML)
- +4 more
- Bortezomib
- NK cells
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Dec 31, 2022
Acute Myeloid Leukemia Trial in Minsk (Expanded haploidentical NK cells)
Recruiting
- Acute Myeloid Leukemia
- Expanded haploidentical NK cells
-
Minsk, Minsk Region, BelarusBelarussian Research Center for Pediatric Oncology, Hematology a
Apr 12, 2022
Ewing Sarcoma, Neuroblastoma, Rhabdomyosarcoma Trial in Milwaukee (Allogeneic HCT, Donor NK Cell Infusion)
Active, not recruiting
- Ewing Sarcoma
- +4 more
- Allogeneic HCT
- Donor NK Cell Infusion
-
Milwaukee, Wisconsin
- +1 more
Apr 5, 2022
Novel Coronavirus Pneumonia Trial in Xinxiang (NK Cells)
Recruiting
- Novel Coronavirus Pneumonia
- NK Cells
-
Xinxiang, Henan, ChinaThe First Affiliated Hospital of Xinxiang Medical University
Aug 31, 2022
Acute Myeloid Leukemia, Acute Myeloid Leukemia Recurrent, Leukemia Trial in Boston (Cytokine-Induced Memory-like Natural Killer
Not yet recruiting
- Acute Myeloid Leukemia
- +3 more
- Cytokine-Induced Memory-like Natural Killer Cells
- +2 more
-
Boston, Massachusetts
- +1 more
Nov 22, 2023
Acute Myeloid Leukemia Trial in Minsk (NK cell infusions)
Recruiting
- Acute Myeloid Leukemia
- NK cell infusions
-
Minsk, Minsk Region, BelarusBelarussian Research Center for Pediatric Oncology, Hematology a
Feb 28, 2022
Recurrent Gliosarcoma, Recurrent Supratentorial Glioblastoma, Supratentorial Gliosarcoma Trial in Houston (Cord Blood-derived
Not yet recruiting
- Recurrent Gliosarcoma
- +2 more
- Cord Blood-derived Expanded Allogeneic Natural Killer Cells
- Resection
-
Houston, TexasM D Anderson Cancer Center
May 24, 2022
Plasma Cell Leukemia, Plasma Cell Myeloma Trial in Houston (procedure, biological, other, drug)
Active, not recruiting
- Plasma Cell Leukemia
- Plasma Cell Myeloma
- Autologous Hematopoietic Stem Cell Transplantation
- +6 more
-
Houston, TexasM D Anderson Cancer Center
Aug 18, 2022
High Grade Glioma Trial in Columbus (NK cells)
Not yet recruiting
- High Grade Glioma
- NK cells
-
Columbus, OhioNationwide Children's Hospital
Jan 11, 2022
Neuroblastoma, High-Risk Trial in New York (cyclophosphamide, NK cells, hu3F8)
Active, not recruiting
- Neuroblastoma
- High-Risk
- cyclophosphamide
- +3 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Feb 14, 2022
Multiple Myeloma, Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma Trial in Minneapolis (Nicotinamide Expanded Haploidentical
Completed
- Multiple Myeloma
- +7 more
- Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells
-
Minneapolis, MinnesotaMasonic Cancer Center, University of Minnesota
Nov 2, 2022
Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Tumor (BPDCN), Relapse Leukemia Trial in Taiyuan (CD123 targeted
Recruiting
- Acute Myeloid Leukemia
- +3 more
- CD123 targeted CAR-NK cells
-
Taiyuan, Shanxi, ChinaShanxi Bethune Hospital
Aug 28, 2023
T Cells and Natural Killer Cells Expression in Immune
Not yet recruiting
- Immune Thrombocytopenic Purpura
- Laboratory investigations for control
- Laboratory investigations for patients
- (no location specified)
Oct 13, 2021
Natural Killer T Cells ExpressingInvariant T Receptor :
Not yet recruiting
- Systemic Lupus Erythematosus
- Physiopathology
- Blood sample
-
Tours, FranceUniversity Hospital
May 12, 2023
Allogeneic Stem Cell Transplant Recipient, Blasts 10 Percent or More of Bone Marrow Nucleated Cells, Recurrent Acute Myeloid
Recruiting
- Allogeneic Stem Cell Transplant Recipient
- +3 more
- Cytarabine Hydrochloride
- +2 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Feb 7, 2022